Physician
Hematology
Dr. Naval G. Daver, MD
|
|
Give Review
Naval Daver works in the field of Hematology. He graduated from Baylor College of Medicine. Naval Daver is a published MD. He published 58 publications, including: 'Acute myeloid leukemia: advancing clinical trials and promising therapeutics.' He accepts Medicare.
Publications
- Synchronous del5q myelodysplastic syndrome (del5qMDS) and adult B-cell Acute lymphoblastic leukemia (B-ALL) with TET2 and TP53 mutations.
- Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal ...
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed Acute myeloid leukemia and high-risk myelodysplastic syndrome.
- Clinical implications of TP53 mutations in Myelodysplastic syndromes treated with hypomethylating agents.
- Acute myeloid leukemia: advancing clinical trials and promising therapeutics.
- Improvement in clinical outcome of FLT3 ITD mutated Acute myeloid leukemia patients over the last one and a half decade.
- Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive Acute lymphoblastic leukaemia: a single-centre, phase...
- Sorafenib and novel multikinase inhibitors in AML.
- Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
- Myelopathy following intrathecal chemotherapy in adults: a single institution experience.
- Secondary Mutations as Mediators of Resistance to Targeted Therapy in Leukemia.
- Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed Acute myeloid leukemia and Acute lymphoblastic leukemia.
- Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in Acute myeloid ...
- A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed / Refractory Acute Lymphoblastic Leukemia.
- Characteristics of Sweet Syndrome in Patients With Acute Myeloid Leukemia.
- Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with Acute myeloid leukemia and myelodysplastic syndrome.
- Incidence of secondary neoplasms in patients with Acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid p...
- Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory Acute lymphoblastic leukemia.
- Outcome of patients with low-risk and intermediate-1-risk Myelodysplastic syndrome after hypomethylating agent failure: A Report on Behalf of the MDS Clinical Research...
- Clinical characteristics and outcomes in patients with Acute promyelocytic leukaemia and hyperleucocytosis.
- Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant Anemia.
- Clinical significance of microcytosis in patients with primary myelofibrosis.
- The effect of decitabine dose modification and myelosuppression on response and survival in patients with Myelodysplastic syndromes.
- Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis.
- Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with Acute lymphoblastic leukemia (ALL).
- A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia.
- Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic Leukemia post clofarabine failure.
- Pernicious Anemia With Spuriously Normal Vitamin B12 Level Might Be Misdiagnosed As Myelodysplastic Syndrome.
- Extramedullary B Lymphoblastic Leukemia/Lymphoma (B-ALL/B-LBL): A Diagnostic Challenge.
- Impact of comorbidities by ACE-27 in the revised-IPSS for patients with Myelodysplastic syndromes.
- Prognostic Implications of Chromosome 17 Abnormalities in the Context of Monosomal Karyotype in Patients With Acute Myeloid Leukemia and Complex Cytogenetics.
- Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy.
- Allogeneic stem cell transplantation as initial salvage for patients with Acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy.
- The combination of Hyper-CVAD plus nelarabine as frontline therapy in adult T cell Acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (LL)-MD Anderson c...
- Effect of NPM1 and FLT3 Mutations on the Outcomes of Elderly Patients With Acute Myeloid Leukemia Receiving Standard Chemotherapy.
- Biological and Clinical Features of Trisomy 21 in Adult Patients With Acute Myeloid Leukemia.
- Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤ 60 years with newly diagnosed Acute myeloid leukemia (AML).
- Modest activity of pomalidomide in patients with myelofibrosis and significant Anemia.
- A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of Myelodysplastic syndrome.
- Phase II study of azacytidine plus sorafenib in patients with Acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
- Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced Myeloid malig...
- Treatment of hairy cell Leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options.
- The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia.
- Allogeneic hematopoietic stem Cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case-control study.
- Prognostic significance of 11q23 aberrations in adult Acute myeloid leukemia and the role of allogeneic stem cell transplantation.
- FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic Leukemia.
- Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with Acute myeloid leukemia.
- Molecular targeted therapy in Acute myeloid leukemia.
- Epidemiology of neurocysticercosis in Houston, Texas.
- Successful Treatment of Intracranial Hemorrhage with Recombinant Activated Factor VII in a Patient with Newly Diagnosed Acute Myeloid Leukemia: A Case Report and Revie...
- A single case of rosai-dorfman Disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine.
- Extramedullary Acute myeloid leukemia: leukemic pleural effusion, case report and review of the literature.
- Bifid liver in a patient with diaphragmatic hernia.
- Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy.
- Primary gastric chorioadenoCarcinoma: a needle in a haystack.
- Outcomes of treatment for hematogenous Staphylococcus aureus vertebral osteomyelitis in the MRSA ERA.
- Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis.
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- Brain Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
Baylor College of Medicine -
Grant Medical College
Drug Facts
| NPI NUMBER | 1740422823 | |
| NPPES Provider LastName | DAVER | |
| NPPES Provider FirstName | NAVAL | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 660.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 20.0 | |
| Percent Opioid Claims | 3.03 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1740422823 |
| Last Name Of The Provider | DAVER |
| First Name Of The Provider | NAVAL |
| View All |
Similar Doctors
|
|
Dr. Mark J. Routbort, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephan J. Dorkhom, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert A. Wolff, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Charles L. Yen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cesar A. De Las Casas, MD |
|
|
Dr. Vivek Subbiah, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bryan K. Kee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Munir Shahjahan, MD |
|
|
Dr. Michael J. Keating, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shahab A. Khan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Courtney N. Miller-Chism, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pei Lin, MD |
|
|
Dr. Ravin Ratan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Brian M. Thomas |